[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:blastic-plasmacytoid-dendritic-cell-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":78,"states":83},"Blastic Plasmacytoid Dendritic Cell Neoplasm",11,10,[8,16,23,29,35,41,47,53,59,65,71],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04216524","Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm",[12],"Phase 2","RECRUITING","2026-08-26T02:19:29.922117Z","2026-05-05T02:43:29.468067Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03113643","SL-401 in Combination With Azacitidine or Azacitidine\u002FVenetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[20],"Phase 1","2026-08-26T02:16:52.995882Z","2026-05-05T02:35:31.898696Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[20],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.730542Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[20],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[20],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.769481Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05476770","Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies",[20],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.744798Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT03779854","Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant",[12],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.279311Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05884333","Cord Blood Transplant in Adults With Blood Cancers",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.262377Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06013423","Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:26.947230Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT05430971","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry",[],"2026-08-26T02:17:42.501124Z","2026-05-13T02:55:06.347858Z",{"nct_id":72,"title":73,"phases":74,"status":75,"updated_at":76,"content_modified":77},"NCT05362773","A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:16:06.901903Z","2026-05-05T02:43:29.384678Z",[79],{"biomarker":80,"count":81,"slug":82},"Interleukin-3 Receptor Subunit Alpha",3,"interleukin-3-receptor-subunit-alpha",[84,88,92,95],{"state":85,"count":86,"slug":87},"Washington",5,"washington",{"state":89,"count":90,"slug":91},"Massachusetts",4,"massachusetts",{"state":93,"count":90,"slug":94},"Texas","texas",{"state":96,"count":81,"slug":97},"California","california"]